Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Peptide patents



      

This page is updated frequently with new Peptide-related patent applications.




Date/App# patent app List of recent Peptide-related patents
07/21/16
20160209430 
 Methods patent thumbnailMethods
The present invention relates to a method of identifying a compound that binds to or modulates the activity of one or more polypeptides encoding one or more receptors that are involved in the detection and perception of fatty acids.. .
Mars Incorporated


07/21/16
20160209422 
 Methods of synthesizing y-aapeptides, y-aapeptide building blocks, y-aapeptide libraries, and y-aapeptide inhibitors of ab40 aggregates patent thumbnailMethods of synthesizing y-aapeptides, y-aapeptide building blocks, y-aapeptide libraries, and y-aapeptide inhibitors of ab40 aggregates
Embodiments of the present disclosure provide for γ-aapeptides, γ-aapeptide building blocks, methods of making γ-aapeptides and libraries of γ-aapeptides, methods of screening the γ-aapeptide libraries for desired peptidomimetic activity, and the like. The present disclosure also provides for γ-aapeptides that are inhibitors of aβ peptide aggregation, methods of inhibiting and disassembling aβ peptide aggregation, methods of inhibiting the toxicity of aβ aggregates towards n2a neuroblasotma cells, as well as methods and compounds for treating alzheimer's disease..
University Of South Florida


07/21/16
20160209421 
 Macrocyclic peptide,  producing same, and screening method using macrocyclic peptide library patent thumbnailMacrocyclic peptide, producing same, and screening method using macrocyclic peptide library
The present invention provides a macrocyclic peptide having a macrocyclic structure comprised of four or more amino acids. At least two amino acids not adjacent to each other have a hydrophobic side chain and the hydrophobic side chains interact with each other inside the ring of the macrocyclic peptide in a hydrophilic environment..

07/21/16
20160209412 
 Msia-srm assay for biomarker analysis patent thumbnailMsia-srm assay for biomarker analysis
The present disclosure provides assays, methods and signature peptides for the identification and quantification of biomarkers in a sample. In particular, the present disclosure relates to the development of mass spectrometric immunoassays with selected reaction monitoring mass spectrometry (msia-srm ms) platforms for biomarker analysis.
Nuclea Biotechnologies, Inc.


07/21/16
20160209317 
 Method patent thumbnailMethod
The invention relates to a new method of determining the presence, absence, number or position(s) of one or more post-translational modifications in a peptide, polypeptide or protein. The invention uses transmembrane pores..
Isis Innovation Limited


07/21/16
20160208335 
 Use of rhoa in cancer diagnosis and inhibitor screening patent thumbnailUse of rhoa in cancer diagnosis and inhibitor screening
Disclosed are a novel method of detecting cancer, a method of screening inhibitors and anticancer agents that target cancer-related molecules, rhoa polypeptide having mutation and a polynucleotide encoding the polypeptide as a therapeutic agent for cancer, and a method of detecting cancer using the polypeptide or polynucleotide. Also disclosed are a vector and a host cell comprising the polynucleotide, a method of screening therapeutic agents for cancer comprising the polypeptide and/or the polynucleotide, and a therapeutic agent for cancer comprising sirna having a silencing effect on rhoa mutant..
Chugai Seiyaku Kabushiki Kaisha


07/21/16
20160208304 
 Efficient production of peptides patent thumbnailEfficient production of peptides
The present invention relates to processes for the production of peptides, and the peptides produced accordingly. Peptides produced according to the invention may be produced more efficiently than peptides produced according to prior art processes.
Amidebio, Llc


07/21/16
20160208301 
 Polypeptides having xylanase activity and polynucleotides encoding same patent thumbnailPolypeptides having xylanase activity and polynucleotides encoding same
The present invention relates to polypeptides having xylanase activity and catalytic domains and polynucleotides encoding the polypeptides and catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides and catalytic domains..
Novozymes A/s


07/21/16
20160208297 
 Omega3 unsaturated fatty acid enzyme and  producing eicosapentaenoic acid patent thumbnailOmega3 unsaturated fatty acid enzyme and producing eicosapentaenoic acid
Provided is an ω3 desaturase having a high enzymatic activity even at normal temperature. A polypeptide consisting of an amino acid sequence having an identity of 80% or more with the amino acid sequence represented by seq id no: 2 and having ω3 desaturation activity, and a gene therefor..
Nisshin Pharma Inc.


07/21/16
20160208284 
 Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides patent thumbnailExpression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
Herein is reported that for transient transfections the use of the human elongation factor 1 alpha promoter (with intron a) provides for an enhanced productivity (in lc-hc-sm organization), the use of the bovine growth hormone polya signal sequence provides for an enhanced productivity compared to use of the sv40 polya signal sequence, the addition of the hgt to the bgh polya signal sequence results in an increased productivity in vectors containing the hcmv promoter and the vector organization lc(3′-5′)-hc-sm results in improved expression. For stable pools it is reported that pools generated with vectors containing the hef1α promoter show an enhanced productivity in batch analysis, clones generated with vectors containing the hef1α promoter show a reduced number of low producing clones, and clones generated with vectors containing the hef1α promoter show a higher stability of igg expression.
Hoffmann-la Roche Inc.


07/21/16
20160208279 

Rust resistance gene


The present invention relates to new transporter polypeptides, and genes encoding therefor, which can be used to confer upon a plant resistance to one or more biotrophic fungal pathogens.. .
Grains Research And Development Corporation


07/21/16
20160208278 

Antifungal plant proteins, peptides, and methods of use


Provided are transgenic plants expressing mtdef5 antifungal proteins and peptides exhibiting high levels of resistance to susceptible fungi. Such transgenic plants contain a recombinant dna construct comprising a natural or heterologous signal peptide sequence operably linked to a nucleic acid sequence encoding these molecules.
Donald Danforth Plant Science Center


07/21/16
20160208268 

Production of recombinant proteins utilizing non-antibiotic selection methods and the incorporation of non-natural amino acids therein


Provided herein are methods and compositions for expression of a nucleic acid construct comprising nucleic acids encoding a) a recombinant polypeptide, and b) a prototrophy-restoring enzyme in a host cell that is auxotrophic for at least one metabolite. In various embodiments, the host cell is auxotrophic for a nitrogenous base compound or an amino acid.

07/21/16
20160208249 

Compositions and methods for inducing senescence in cancer cells


The invention relates to nucleic acid sequences as well as to modified oligonucleotides (odns) comprising a p52 binding site derived from the ezh2 promoter region, as well as to compositions and methods for treating cancer. The invention relates to peptides derived from p52 as well as to compositions and methods for treating cancer.
Centre Hopitalier Universitaire De Nice


07/21/16
20160208238 

Cell-based composite materials with programmed structures and functions


The present invention is directed to the use of silicic acid to transform biological materials, including cellular architecture into inorganic materials to provide biocomposites (nanomaterials) with stabilized structure and function. In the present invention, there has been discovered a means to stabilize the structure and function of biological materials, including cells, biomolecules, peptides, proteins (especially including enzymes), lipids, lipid vesicles, polysaccharides, cytoskeletal filaments, tissue and organs with silicic acid such that these materials may be used as biocomposites.
Stc.unm


07/21/16
20160208237 

Modifications of peptide compositions to increase stability and delivery efficiency


The disclosed invention relates to methods of modifying peptide compositions to increase stability and delivery efficiency. Specifically, the disclosed invention relates to methods to increase the stability and delivery efficiency of protein kinase c (pkc) modulatory peptide compositions.
Kai Pharmaceuticals, Inc.


07/21/16
20160208235 

Detection and removal of misfolded proteins/peptides


The invention concerns the field of detecting and quantifying misfolded proteins/peptides. In particular the detection and quantification of misfolded proteins/peptides in body fluids, on cell surfaces of humans and mammals, the detection of misfolded proteins/peptides in reagents to be tested for scientific research and/or diagnostic use and in pharmaceutical medication or their additives and it concerns as well the removal of misfolded proteins/peptides from reagents to be tested for scientific research and/or for diagnostic purposes and from pharmaceutical medication or their additives.
Oxprotect Gmbh


07/21/16
20160208229 

Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same


The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
Novozymes Inc.


07/21/16
20160208224 

2-deoxy-scyllo-inosose reductase


[solution] a 2-deoxy-scyllo-inosose reductase which is originated from a microorganism capable of utilizing (−)-vibo-quercitol and has the properties (a) to (c): (a) the enzyme has a catalytic activity of converting 2-deoxy-scyllo-inosose to (−)-vibo-quercitol; (b) the activity of the enzyme becomes maximum at a ph value of 7.0 to 9.0; and (c) a polypeptide moiety in the enzyme has a molecular mass of about 36 kda as measured by sds-polyacrylamide electrophoresis.. .

07/21/16
20160208221 

Compositions and methods using capsids resistant to hydrolases


Novel processes and compositions are described which use viral capsid proteins resistant to hydrolases to prepare virus-like particles to enclose and subsequently isolate and purify target cargo molecules of interest including nucleic acids such as sirnas and shrnas, mirnas, messenger rnas, small peptides and bioactive molecules.. .
Apse, Llc


07/21/16
20160208020 

Peptide core-based multi-arm linkers


The present disclosure provides various molecular constructs having a targeting element and/or an effector element. Methods for treating various diseases using such molecular constructs are also disclosed..
Immunwork Inc.


07/21/16
20160208017 

Mutant interleukin-2 polypeptides


The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the il-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant il-2 polypeptides, polynucleotide molecules encoding the mutant il-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules.
Roche Glycart Ag


07/21/16
20160207986 

Immobilized single domain antigen-binding molecules


The immobilisation of single domain antigen binding fragments of antibodies naturally devoid of light chains, or protein domains functionally equivalent thereto, onto a solid surface through covalent cross-linking is described. The binding fragments are devoid of any appended polypeptide tail or linking group.
Bac Ip B.v.


07/21/16
20160207984 

High affinity synbodies for influenza


Composition of synbodies that bind influenza. The synbodies are composed of two peptides joined on a scaffold..
Arizona Board Of Regents On Behalf Of Arizona State University


07/21/16
20160207981 

Non-immunogenic single domain antibodies


The invention provides modifications within human or humanized single domain antibody fragments (sdabs) that prevent recognition by pre-existing antibodies, to isolated polypeptides that include these modifications, and to methods and uses thereof.. .
Inhibrx Lp


07/21/16
20160207979 

Multivalent heteromultimer scaffold design and constructs


Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof.
Zymeworks Inc.


07/21/16
20160207975 

Cgrp agonist peptides


The embodiments provide a calcitonin gene-related peptide (cgrp) agonist peptide or pharmaceutically acceptable salt thereof, including pharmaceutical compositions comprising a cgrp agonist peptide. The embodiments further provide treatment methods, including method of treating metabolic disorders and metabolic disorders selected from metabolic syndrome, diabetes and obesity.

07/21/16
20160207974 

Engineered polypeptides having enhanced duration of action and reduced immunogenicity


Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.

07/21/16
20160207971 

Hsp20 inhibits amyloidogenesis and neurotoxicity


The present inventions are compositions and methods of using at least a portion of an isolated and purified α-crystallin polypeptide that includes one or more β-pleated sheets and that prevents neurotoxicity and amyloidogenesis.. .
The Texas A&m University System


07/21/16
20160207970 

Polypeptide for the protection against heart ischemia-reperfusion injury


Can be used for the treatment and prophylaxis of heart ischemia-reperfusion injury.. .

07/21/16
20160207969 

Clostridium difficile targeting moieties and constructs comprising said moieties


In certain embodiments, constructs are provided that selectively/preferentially inhibit and/or kill clostridium difficile. In certain embodiments the constructs comprise a peptide that binds c.
C3 Jian, Inc.


07/21/16
20160207966 

Mutated immunoglobulin-binding polypeptides


A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a b or c domain of staphylococcus protein a, as specified by seq id no 1 or seq id no 2, or of protein z, as specified by seq id no 3, wherein at least the glutamine residue at position 15 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of the polypeptide, as well as separation matrices comprising the multimers or polypeptides..
Ge Healthcare Bio-sciences Ab


07/21/16
20160207964 

Designing a soluble full-length hiv-1 gp41 trimer


Described herein is a soluble hiv-1 retrovirus transmembrane glycoprotein gp41 trimer (soc-gp41m-fd) containing a partial ectodomain and the cytoplasmic domain, that is fused to the small outer capsid (soc) protein of bacteriophage t4 and the foldon domain of the bacteriophage t4 fibritin (fd). The gp41 trimer that has a prehairpin structure could be utilized to understand the mechanism of viral entry and as a candidate for development of hiv-1 vaccines, diagnostics and therapeutics.
The Catholic University Of America


07/21/16
20160207960 

Peptides inhibiting cold-inducible rna binding protein activity


Disclosed are pharmaceutical compositions comprising a cirp inhibitor. Methods of treating a subject suffering from an inflammatory condition comprising administering to said subject a cirp inhibitor are also described herein..
The Feinstein Institute For Medical Research


07/21/16
20160207959 

Methods and compositions for treatment of cartilage and disc tissue pathologies


An isolated polypeptide comprising a peptide selected from: i) dhx1sdnyt, wherein x1 is l or h (seq id no:3); ii) a conservative variant of i) iii) a fragment of i) or ii); wherein the conservative variant and/or fragment retains biological activity and the peptide is 15 or less amino acids as well as recombinant cells, and uses thereof.. .
The Royal Institution For The Advancement Of Learning/mcgill University


07/21/16
20160207958 

Method for producing dipeptide derivative containing disubstituted amino acid residue


A method for producing a dipeptide that has a protected n-terminal and is represented by formula (1) or a salt of the dipeptide, said method comprising condensing an α-monosubstituted amino acid that has a protected n-terminal and is represented by formula (2) or glycine or a salt thereof with a disubstituted amino acid that is represented by formula (3) or a salt thereof in the presence of a condensing agent [in each of the formulae, substituents are as defined in the description or the like].. .
Nagase & Co., Ltd.


07/21/16
20160207957 

Amino diacids containing peptide modifiers


The present invention relates to peptide modifier compounds of formula (1), or a salt thereof, wherein: a is an integer from 1 to 10, more preferably from 1 to 3; b is an integer from 0 to 7; z is a terminal group and y is a bivalent group. Further aspects of the invention relate to intermediates in the preparation of compounds of formula (1), and the use of compounds of formula 1 in the synthesis of peptide derivatives..
Chemical & Biopharmaceutical Laboratories Of Patras S.a.


07/21/16
20160206753 

Modularly assembled small molecules for the treatment of myotonic dystrophy type 1


To study rna function using small molecules, we designed bioactive, modularly assembled small molecules that target the noncoding expanded rna repeat that causes myotonic dystrophy type 1 (dm1), r(cug)exp. Different modular assembly scaffolds were investigated including polyamines, alpha-peptides, beta-peptides, and peptide tertiary amides (pt as).
The Scripps Research Institute


07/21/16
20160206749 

Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells


Cholesterol moieties are linked to specific ends of double-stranded rna, preferably a small, interfering (si)rna or to a dshybrid. The dshybrid has one strand comprised of dna and one strand comprised of rna.
Marina Biotech, Inc.


07/21/16
20160206741 

Hydrogels for delivery of therapeutic compounds


In some aspects, methacrylate co-polymers crosslinked with an enzymatically cleavable peptide linker are provided and may be used for the oral delivery of a therapeutic. The peptide linker may be cleavable by an enzyme in the small intestine and may allow for the delivery of a therapeutic protein or nucleic acid to the small intestine.
Board Of Regents, The University Of Texas System


07/21/16
20160206726 

Immunotherapy


The invention provides an agent comprising: a cyclic peptide comprising a t cell antigen peptide; wherein in cyclised form the t cell antigen peptide is not capable of eliciting a t cell response; and wherein the t cell antigen peptide is rendered capable of eliciting a t cell response by selective cleavage of one or more cleavage sites in the cyclic peptide. The agent may be used to prevent or treat a condition characterised by the presence of unwanted cells..
The University Of Birmingham


07/21/16
20160206716 

Compositions comprising angiogenic factors and methods of use thereof


The present invention provides recombinant listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a pest-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.. .
The Trustees Of The University Of Pennsylvania


07/21/16
20160206715 

Specific multivalent virus-like particle vaccines and uses thereof


The invention provides a vlp free of a viral genome comprising two or more display polypeptides, nucleic acid molecules, polymers of the nucleic acid, lipopolysaccharides, lipopeptides, peptidoglycans and/or small molecules.. .
The Board Of Trustees Of The Leland Standford Junior University


07/21/16
20160206714 

Diagnostic test and treatment/prevention of alzheimer's disease


The present invention includes a method for diagnosis and treatment and prevention of alzheimer's disease comprising obtaining a biological sample from a subject suspected of having alzheimer's disease; determining the level of expression of hsp 27, wherein a statistically significant increase in hsp27 protein expression in the sample as compared to a sample from a non-alzheimer's patient is indicative that the subject has alzheimer's disease; and modifying the treatment of the subject as a result of the detection of alzheimer's disease by providing the subject with standard therapy or a single vector expressing an aβ42 trimer peptide and optionally the addition of an aβ42 peptide, which elicits an immune reaction against the aβ42 peptide, thereby preventing the accumulation of aβ42 peptide and therefore preventing or treating alzheimer's disease.. .
Vitruvian Biomedical, Inc.


07/21/16
20160206695 

Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use


The present disclosure provides chimeric proteins having an n-terminus coupled to a c-terminus, wherein the n-terminus comprises an n-terminal portion of fibroblast growth factor (fgf) 2 and the c-terminus comprises a portion of an fgf1 protein, wherein the chimeric protein comprises at least 95% sequence identity to seq id no: 9, 10, 11, 12 or 13. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids.
Salk Institute For Biological Studies


07/21/16
20160206694 

Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity


The invention includes an isolated peptide comprising all or part of the amino acid sequence: egklssndte gglckeflhp skvdlpr (seq id no: 1), wherein the peptide inhibits calcium channel activity. The peptides of the invention are useful for preventing or treating cancer..
Soricimed Biopharma Inc.


07/21/16
20160206692 

Engineered integrin binding peptide compositions


Engineered peptides that bind with high affinity (low equilibrium dissociation constant (kd)) to the cell surface receptors of fibronectin (α5β1) or vitronectin (αvβ3 and αvβ5 integrins) are disclosed as useful as imaging tissue. These peptides are based on a molecular scaffold into which a subsequence containing the rgd integrin-binding motif has been inserted.
The Board Of Trustees Of The Leland Stanford Junior University


07/21/16
20160206691 

Treatment of tumours using peptide-protein conjugates


Provided herein are methods for modulating tumour stroma, normalizing tumour vasculature and/or improving vascular function in a tumour, comprising exposing a tumour to an effective amount of a peptide-protein conjugate comprising a light polypeptide and a tumour homing peptide. Also provided are methods for treating tumours and increasing the survival time of tumour-bearing patients, comprising administering an effective amount of a peptide-protein conjugate comprising a light polypeptide and a tumour homing peptide..
The University Of Western Australia


07/21/16
20160206683 

Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide


Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes.

07/21/16
20160206682 

Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide


Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes.

07/21/16
20160206680 

Anti-trypanosome compounds and treatments


A novel structural class of highly n-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.. .
The Regents Of The University Of California


07/21/16
20160206575 

Inhibition of biofilm organisms


The present invention relates to a product comprising at least two antibiofilm agents wherein at least one of the antibiofilm agents is an antimicrobial peptide. The second antibiofilm agent is cysteamine.
Novabiotics Limited


07/21/16
20160206543 

Synergistic compositions and methods for mitigating skin irritation and enhancing skin barrier function


Methods and compositions are provided for mitigating the irritation of mammalian skin cells, protecting cell viability and/or enhancing cell-cell junction, thus improving skin barrier function. The compositions contain combinations of acetyl hexapeptides and a cosmetically and/or pharmaceutically acceptable carrier.
Gojo Industries, Inc.


07/21/16
20160205989 

Beverage with collagen and additional additives


The present invention concerns a beverage having water and a concentration range of about 0.001 grams per liter to 8.44 grams per liter of collagen, wherein the collagen is hydrolyzed. The collagen concentration range may be between 1 milligram per liter to about 8440 milligram per liter or 1 parts per million to about 8440 parts per million.
Welldrinks Ltd


07/14/16
20160202267 

Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides


The invention relates to a method for obtaining april-binding peptides. With this method april-binding peptides may be obtained and/or selected.
Aduro Biotech Holdings, Europe B.v.


07/14/16
20160202266 

Ultrathin calcinated films on a gold surface for highly effective laser desorption/ ionization of biomolecules


A nanoscale calcinated silicate film fabricated on a gold substrate for highly effective, matrix-free laser desorption ionization mass spectrometry (ldi-ms) analysis of biomolecules. The calcinated film is prepared by a layer-by-layer (lbl) deposition/calcination process wherein the thickness of the silicate layer and its surface properties are precisely controlled.
The Regents Of The University Of California


07/14/16
20160202245 

Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells


The present invention pertains to a method for directly determining the biological activity of a neurotoxin polypeptide in cells, comprising the steps of: a) incubating cells susceptible to neurotoxin intoxication with a neurotoxin polypeptide for a time and under conditions which allow for the neurotoxin polypeptide to exert its biological activity; b) fixing the cells and, optionally, permeabilizing the cells with a detergent; c) contacting the cells with at least a first capture antibody specifically binding to the non-cleaved and neurotoxin-cleaved substrate and with at least a second capture antibody specifically binding to the cleavage site of the neurotoxin-cleaved substrate, under conditions which allow for binding of said capture antibodies to said substrates; d) contacting the cells with at least a first detection antibody specifically binding to the first capture antibody, under conditions which allow for binding of said first detection antibody to said first capture antibody, thus forming first detection complexes, and at least a second detection antibody specifically binding to the second capture antibody, under conditions which allow for binding of said second detection antibody to said second capture antibody, thus forming second detection complexes; e) determining the amount of the first and second detection complexes of step d), and f) calculating the amount of substrate cleaved by said neurotoxin polypeptide in said cells by means of the second detection complexes, thereby determining the biological activity of said neurotoxin polypeptide in said cells. The invention further provides for a kit for carrying out the method of the invention..
Merz Pharma Gmbh & Co. Kgaa


07/14/16
20160201146 

Novel reporter constructs for compound screening


The instant description provides reporter constructs, transgenic cells, and transgenic organisms and methods for identifying agents that can regulate gene expression and improve plant performance and yield. Compounds that increase plant performance or yield are identified by contacting a test compound with a plant cell that comprises a target promoter sequence operably linked to a polynucleotide sequence encoding a dna sequence-specific transactivator, and a reporter polynucleotide that is operably linked to a promoter sequence that is recognized by the dna sequence-specific transactivator.
Koch Biological Solutions, Llc


07/14/16
20160201113 

Kits and methods for detecting methylated dna


The present invention relates to an in vitro method for detecting methylated dna comprising (a) coating a container with a polypeptide capable of binding methylated dna; (b) contacting said polypeptide with a sample comprising methylated and/or unmethylated dna; and (c) detecting the binding of said polypeptide to methylated dna. In a preferred embodiment, said method further comprises step (d) analyzing the detected methylated dna by sequencing.
Sequenom, Inc.


07/14/16
20160201099 

Chimeric non-ribosomal peptide synthetase


The present disclosure provides novel compositions and methods for the production and use of polynucleotide sequences encoding a chimeric non-ribosomal peptide synthetase (nrps) fusion protein for the biosynthesis of n-acylglycine biosurfactants within a heterologous expression system.. .
Dow Agrosciences Llc


07/14/16
20160201084 

Wheat ms1 polynucleotides, polypeptides, and methods of use


Compositions and methods are capable of modulating male fertility in a plant. Compositions comprise polynucleotides and polypeptides, and fragments and variants thereof, which modulate male fertility.
Pioneer Hi Bred International Inc


07/14/16
20160201082 

Axmi422 toxin gene and methods for its use


Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.
Athenix Corp.


07/14/16
20160201077 

Plants with increased tolerance and/or resistance to environmental stress and increased biomass production


This invention relates generally to a plant cell with increased tolerance and/or resistance to environmental stress and increased biomass production as compared to a corresponding non-transformed wild type plant cell by increasing or generating one or more activities of polypeptides associated with abiotic stress responses and abiotic stress tolerance in plants.. .
Basf Plant Science Gmbh


07/14/16
20160201067 

Composition for enhancing transgene expression in eukaryotic cells and enhancing production of a target protein encoded by a transgene


Production of dna vectors with the inserted gene of a target protein and the production of recombinant protein in eukaryotic cell cultures is disclosed. A composition for the intensive production of target protein in eukaryotic cells comprises a dna vector with the inserted gene of a target protein and an agonist of cell receptors belonging to the pattern recognition receptor (prr) family selected from the following agonists: tlr2, or tlr4, or tlr5, or tlr7, or tlr8, or tlr9, or nod1 receptor, or nod2 receptor, used in an optimal ratio.
Silezia Group Pte. Ltd


07/14/16
20160201053 

Inducible mutagenesis of target genes


The present invention relates generally to mutagenesis of target genes that takes advantage of the natural mutagenic capabilities of b cells, and enhances those capabilities by bringing the process of diversification under control. The invention provides a method for rapidly and inducibly generating point mutations and other types of diversification in expressed genes, such as antibody genes.
University Of Washington


07/14/16
20160201048 

Stabilized recombinant expression plasmid vector in hafnia alvei and applications thereof


One aspect of the present disclosure relates to a stabilized recombinant expression plasmid vector comprising a polynucleotide encoding an antitoxin gene which expresses a polypeptide that neutralizes a polypeptide toxic to a host cell, the toxic polypeptide being expressed by a toxin gene in the host cell, and a polynucleotide encoding a polypeptide expression product, and the stabilized recombinant expression plasmid vector is derived from a hafnia alvei autonomously replicable backbone plasmid. Other aspects of the present disclosure relate to a transformant transformed with the stabilized recombinant expression plasmid vector disclosed herein, a method of producing biobased cadaverine using the transformant disclosed herein, and biobased cadaverine prepared by the method disclosed herein.
Cathay R&d Center Co., Ltd.


07/14/16
20160201047 

Modified factor ix polypeptides and uses thereof


Nucleic acid molecules encoding modified factor ix (fix) polypeptides and uses thereof are provided. Such modified fix polypeptides include fixa and other forms of fix.
Catalyst Biosciences, Inc.


07/14/16
20160201043 

Cellulase enzymes having a modified linker and reduced lignin binding


Provided are modified cellulase enzymes exhibiting increase cellulose-hydrolyzing activity in the presence of lignin and/or reduced binding to lignin comprising modified linker peptides comprising one or more amino acid substitutions, insertions, or deletions that result in (a) a decrease in the calculated isoelectric point of the linker peptide and/or (b) an increase in the ratio of threonine:serine in the linker peptide relative to a parental linker peptide from which said modified linker peptide is derived. Also provided are genetic constructs comprising nucleic acid sequences encoding for modified cellulase enzymes, methods for the production of the modified cellulase enzymes from host strains and a process for hydrolysing cellulose with the modified cellulases in the presence of lignin..
Iogen Energy Corporation


07/14/16
20160201033 

Hematopoietic cell e-selectin/l-selectin ligand polypeptides and methods of use thereof


The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.. .

07/14/16
20160201028 

Cell culture medium and process for controlling a-amidation and/or c-terminal amino acid cleavage of polypeptides


The present invention is related to a cell culture medium for reducing the c-terminal heterogeneity of a polypeptide expressed in cell-culture, wherein the medium comprises at least one essential trace element in an effective amount, and to a cell culture process for reducing c-terminal heterogeneity of a protein, in which process an essential trace element is used.. .
Lek Pharmaceuticals D.d.






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Peptide for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Peptide with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3408

4862

0 - 1 - 109